AstraZeneca Stock Price, News & Analysis (NYSE:AZN)

$34.23 +0.59 (+1.75 %)
(As of 02/21/2018 02:01 PM ET)
Previous Close$33.64
Today's Range$33.60 - $34.54
52-Week Range$28.43 - $36.70
Volume3.35 million shs
Average Volume4.49 million shs
Market Capitalization$85.06 billion
P/E Ratio28.96
Dividend Yield4.04%
Beta0.74

About AstraZeneca (NYSE:AZN)

AstraZeneca logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:AZN
CUSIPN/A
Phone+44-20-73045000

Debt

Debt-to-Equity Ratio0.93%
Current Ratio0.80%
Quick Ratio0.62%

Price-To-Earnings

Trailing P/E Ratio28.9576271186441
Forward P/E Ratio20.50
P/E Growth2.05

Sales & Book Value

Annual Sales$22.47 billion
Price / Sales3.86
Cash Flow$3.37 per share
Price / Cash10.16
Book Value$6.57 per share
Price / Book5.21

Profitability

Trailing EPS$1.18
Net Income$3.00 billion
Net Margins13.36%
Return on Equity34.74%
Return on Assets8.52%

Miscellaneous

Employees59,700
Outstanding Shares2,532,790,000

AstraZeneca (NYSE:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a semiannual dividend on Monday, February 5th. Stockholders of record on Friday, February 16th will be given a dividend of $0.95 per share on Monday, March 19th. This represents a dividend yield of 5.62%. The ex-dividend date is Thursday, February 15th. View AstraZeneca's Dividend History.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

Shares of AstraZeneca split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were issued to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) posted its earnings results on Friday, February, 2nd. The company reported $1.30 EPS for the quarter, beating the consensus estimate of $0.44 by $0.86. The business had revenue of $5.78 billion for the quarter, compared to analysts' expectations of $5.49 billion. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The company's revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.21 EPS. View AstraZeneca's Earnings History.

When will AstraZeneca make its next earnings announcement?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for AstraZeneca.

What guidance has AstraZeneca issued on next quarter's earnings?

AstraZeneca updated its FY18 earnings guidance on Friday, February, 2nd. The company provided EPS guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.64.

Where is AstraZeneca's stock going? Where will AstraZeneca's stock price be in 2018?

19 brokers have issued twelve-month price targets for AstraZeneca's shares. Their forecasts range from $35.00 to $42.00. On average, they anticipate AstraZeneca's share price to reach $38.40 in the next year. View Analyst Ratings for AstraZeneca.

Who are some of AstraZeneca's key competitors?

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:

  • Pascal Soriot, Executive Director and Chief Executive Officer (Age 57)
  • Marc Dunoyer, Executive Director, Chief Financial Officer (Age 64)
  • Fiona Cicconi, Executive Vice-President, Human Resources
  • Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
  • Pam P. Cheng, Executive Vice President - Operations and Information Technology (Age 45)
  • Ruud Dobber, Executive Vice President, North America
  • Bahija Jallal Ph.D., Executive Vice President, MedImmune
  • Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
  • Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
  • Leon Wang, Executive Vice President - Asia Pacific

Who owns AstraZeneca stock?

AstraZeneca's stock is owned by a number of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.47%), BlackRock Inc. (0.25%), Schafer Cullen Capital Management Inc. (0.17%), Wells Fargo & Company MN (0.17%), Farallon Capital Management LLC (0.15%) and Redmile Group LLC (0.08%). View Institutional Ownership Trends for AstraZeneca.

Who sold AstraZeneca stock? Who is selling AstraZeneca stock?

AstraZeneca's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, BlackRock Inc., Millennium Management LLC, Redmile Group LLC, Wells Fargo & Company MN, Assetmark Inc., Schafer Cullen Capital Management Inc. and TIAA CREF Investment Management LLC. View Insider Buying and Selling for AstraZeneca.

Who bought AstraZeneca stock? Who is buying AstraZeneca stock?

AstraZeneca's stock was acquired by a variety of institutional investors in the last quarter, including American International Group Inc., Hardman Johnston Global Advisors LLC, Two Sigma Investments LP, Arrowstreet Capital Limited Partnership, Farallon Capital Management LLC, Quantitative Investment Management LLC, Fisher Asset Management LLC and OLD Republic International Corp. View Insider Buying and Selling for AstraZeneca.

How do I buy AstraZeneca stock?

Shares of AstraZeneca can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AstraZeneca stock can currently be purchased for approximately $34.23.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $85.06 billion and generates $22.47 billion in revenue each year. The company earns $3.00 billion in net income (profit) each year or $1.18 on an earnings per share basis. AstraZeneca employs 59,700 workers across the globe.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The company can be reached via phone at +44-20-73045000 or via email at [email protected]


MarketBeat Community Rating for AstraZeneca (AZN)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  505 (Vote Outperform)
Underperform Votes:  873 (Vote Underperform)
Total Votes:  1,378
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AstraZeneca (NYSE:AZN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.582.582.532.43
Ratings Breakdown: 1 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.40$37.00$36.60$36.09
Price Target Upside: 14.35% upside5.50% upside10.08% upside21.32% upside

AstraZeneca (NYSE:AZN) Consensus Price Target History

Price Target History for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/20/2018BMO Capital MarketsSet Price TargetBuy$40.00LowView Rating Details
2/6/2018Leerink SwannBoost Price TargetMarket Perform -> Market Perform$36.00 -> $38.00MediumView Rating Details
2/5/2018Sanford C. BernsteinBoost Price TargetOutperform$40.00 -> $42.00HighView Rating Details
12/29/2017JPMorgan Chase & Co.UpgradeNeutral -> OverweightLowView Rating Details
10/18/2017CitigroupUpgradeBuyN/AView Rating Details
10/17/2017CowenReiterated RatingHold$37.00N/AView Rating Details
10/16/2017Credit Suisse GroupUpgradeNeutral -> OutperformN/AView Rating Details
9/25/2017BNP ParibasUpgradeNeutral -> OutperformMediumView Rating Details
9/14/2017Liberum CapitalDowngradeBuy -> HoldLowView Rating Details
9/6/2017NatixisUpgradeNeutral -> BuyLowView Rating Details
9/1/2017ArgusReiterated RatingBuy$35.00LowView Rating Details
8/9/2017InvestecUpgradeHold -> BuyLowView Rating Details
8/9/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
8/1/2017Pareto SecuritiesUpgradeSell -> HoldLowView Rating Details
7/28/2017Morgan StanleyDowngradeOverweight -> Equal WeightHighView Rating Details
7/13/2017Goldman Sachs GroupReiterated RatingSellHighView Rating Details
7/13/2017BarclaysReiterated RatingOverweightHighView Rating Details
4/10/2017Jefferies GroupReiterated RatingBuy -> HoldLowView Rating Details
2/21/2017Berenberg BankReiterated RatingBuyN/AView Rating Details
11/11/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
11/11/2016Beaufort SecuritiesReiterated RatingHoldN/AView Rating Details
11/10/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
11/10/2016Bank of AmericaReiterated RatingBuy$41.37N/AView Rating Details
11/10/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
2/28/2016Drexel HamiltonInitiated CoverageBuyN/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

AstraZeneca (NYSE:AZN) Earnings History and Estimates Chart

Earnings by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE AZN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018        
2/2/2018Q4 2017$0.44$1.30$5.49 billion$5.78 billionViewListenView Earnings Details
11/9/2017Q3$0.57$1.12$6.00 billion$6.23 billionViewN/AView Earnings Details
7/27/20176/30/2017$0.41$0.87$5.04 billion$5.05 billionViewN/AView Earnings Details
4/27/20173/31/2017$0.38$0.99$5.40 billion$5.41 billionViewN/AView Earnings Details
2/2/2017Q416$0.51$1.21$5.43 billion$5.59 billionViewListenView Earnings Details
11/10/2016Q316$0.48$1.32$5.95 billion$5.70 billionViewN/AView Earnings Details
7/28/2016Q216$0.76$0.83$5.56 billion$5.60 billionViewListenView Earnings Details
4/29/2016Q1$0.60$0.51$5.96 billion$6.12 billionViewListenView Earnings Details
2/4/2016Q415$0.88$0.94$6.27 billion$6.40 billionViewN/AView Earnings Details
11/5/2015Q315$0.51$1.03$5.90 billion$5.85 billionViewN/AView Earnings Details
7/30/2015Q2$0.52$1.21$6.02 billion$5.84 billionViewListenView Earnings Details
4/24/2015Q1$1.07$1.08$5.87 billion$6.06 billionViewN/AView Earnings Details
2/5/2015Q314$0.85$0.76$6.68 billion$6.68 billionViewN/AView Earnings Details
11/6/2014Q3$1.04$1.05$6.44 billion$6.54 billionViewN/AView Earnings Details
7/31/2014Q214$1.09$1.30$6.24 billion$6.45 billionViewN/AView Earnings Details
4/29/2014Q114$1.23$1.17$6.32 billion$6.42 billionViewN/AView Earnings Details
2/6/2014Q413$1.22$1.23$6.91 billion$3.84 billionViewN/AView Earnings Details
10/31/2013Q313$1.27$1.21$6.45 billion$6.25 billionViewN/AView Earnings Details
8/1/2013Q213$1.16$1.20$6.24 billion$6.23 billionViewN/AView Earnings Details
4/25/2013$1.36$1.41$6.54 billion$6.39 billionViewN/AView Earnings Details
1/31/2013Q412$1.37$1.56$7.17 billion$7.28 billionViewN/AView Earnings Details
10/25/2012$1.44$1.51ViewN/AView Earnings Details
7/26/2012$1.38$1.53ViewN/AView Earnings Details
4/26/2012$1.73$1.81ViewN/AView Earnings Details
2/2/2012$1.57$1.61ViewN/AView Earnings Details
10/27/2011$1.64$1.71ViewN/AView Earnings Details
7/28/2011$1.74$1.53ViewN/AView Earnings Details
4/27/2011Q1 2011$1.02$1.04ViewN/AView Earnings Details
1/27/2011Q4 2010$0.67$0.68ViewN/AView Earnings Details
10/27/2010Q3 2010$0.76$0.54ViewN/AView Earnings Details
7/30/2010Q2 2010$0.80$0.73ViewN/AView Earnings Details
4/29/2010Q1 2010$0.86$1.02ViewN/AView Earnings Details
10/29/2009Q3 2009$0.68$0.73ViewN/AView Earnings Details
7/30/2009Q2 2009$0.68$0.82ViewN/AView Earnings Details
1/29/2009Q4 2008$0.59$0.63ViewN/AView Earnings Details
4/24/2008Q1 2008$0.60$0.52ViewN/AView Earnings Details
1/31/2008Q4 2007$0.50$0.52ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AstraZeneca (NYSE:AZN) Earnings Estimates

2018 EPS Consensus Estimate: $1.67
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.42$0.42$0.42
Q2 20181$0.40$0.40$0.40
Q3 20181$0.39$0.39$0.39
Q4 20181$0.46$0.46$0.46
(Earnings estimates data provided by Zacks Investment Research)

Dividends

AstraZeneca (NYSE:AZN) Dividend Information

Next Dividend:3/19/2018
Annual Dividend:$1.37
Dividend Yield:4.00%
Dividend Growth:-21.20% (3 Year Average)
Payout Ratio:116.10% (Trailing 12 Months of Earnings)
82.04% (Based on This Year's Estimates)
72.87% (Based on Next Year's Estimates)
Dividend Payments by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2018semiannual$0.955.62%2/15/20182/16/20183/19/2018
7/28/2017None$0.442.98%8/9/20178/11/20179/11/2017
2/3/2017semiannual$0.956.81%2/15/20172/17/20173/20/2017
7/29/2016$0.448/10/20168/12/20169/12/2016
2/5/2016$0.932/17/20162/19/20163/21/2016
2/10/2015semiannual$1.905.57%2/18/20152/20/20153/23/2015
8/1/2014semiannual$0.902.48%8/13/20148/15/20149/15/2014
2/10/2014special$1.902.79%2/19/20142/21/20143/24/2014
8/2/2013semiannual$0.903.52%8/14/20138/16/20139/16/2013
2/1/2013special$1.903.72%2/13/20132/15/20133/18/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for AstraZeneca (NYSE AZN)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

AstraZeneca (NYSE AZN) News Headlines

Source:
DateHeadline
AstraZeneca (AZN) PT Set at $40.00 by BMO Capital MarketsAstraZeneca (AZN) PT Set at $40.00 by BMO Capital Markets
www.americanbankingnews.com - February 20 at 4:50 PM
AstraZeneca Scores FDA First, Time To Capitalize Before Competitors Roll In - Seeking AlphaAstraZeneca Scores FDA First, Time To Capitalize Before Competitors Roll In - Seeking Alpha
seekingalpha.com - February 20 at 8:14 AM
[$$] AstraZeneca: hoist the sales[$$] AstraZeneca: hoist the sales
finance.yahoo.com - February 19 at 5:12 PM
[$$] AstraZeneca wins FDA approval for key cancer drug[$$] AstraZeneca wins FDA approval for key cancer drug
finance.yahoo.com - February 19 at 5:12 PM
FDA OKs expanded use for AstraZenecas Imfinzi - Seeking AlphaFDA OKs expanded use for AstraZeneca's Imfinzi - Seeking Alpha
seekingalpha.com - February 19 at 8:13 AM
AstraZenecas cancer therapy Imfinzi gets FDA nod - MarketWatchAstraZeneca's cancer therapy Imfinzi gets FDA nod - MarketWatch
www.marketwatch.com - February 19 at 8:13 AM
[$$] AstraZeneca hails ‘milestone’ US approval for lung cancer drug[$$] AstraZeneca hails ‘milestone’ US approval for lung cancer drug
finance.yahoo.com - February 19 at 8:13 AM
U.S. FDA approves AstraZenecas immunotherapy for lung cancerU.S. FDA approves AstraZeneca's immunotherapy for lung cancer
finance.yahoo.com - February 17 at 8:11 AM
AstraZenecas immunotherapy drug wins key lung cancer approvalAstraZeneca's immunotherapy drug wins key lung cancer approval
finance.yahoo.com - February 17 at 8:11 AM
Merck’s Diabetes Products in 4Q17Merck’s Diabetes Products in 4Q17
finance.yahoo.com - February 16 at 8:14 AM
AstraZeneca plc (AZN) Receives Average Recommendation of "Hold" from AnalystsAstraZeneca plc (AZN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 13 at 5:36 PM
Opdivo: Bristol-Myers Squibb’s Oncology Blockbuster Drug in 4Q17Opdivo: Bristol-Myers Squibb’s Oncology Blockbuster Drug in 4Q17
finance.yahoo.com - February 13 at 9:32 AM
Why Novartis’s Entresto Could Witness a Robust Demand Trend in 2018Why Novartis’s Entresto Could Witness a Robust Demand Trend in 2018
finance.yahoo.com - February 12 at 9:24 AM
Leerink Swann Comments on AstraZeneca plcs FY2019 Earnings (AZN)Leerink Swann Comments on AstraZeneca plc's FY2019 Earnings (AZN)
www.americanbankingnews.com - February 8 at 5:22 PM
Head to Head Review: Veru (VERU) vs. AstraZeneca (AZN)Head to Head Review: Veru (VERU) vs. AstraZeneca (AZN)
www.americanbankingnews.com - February 7 at 11:14 AM
Leerink Swann Comments on AstraZeneca plcs Q1 2018 Earnings (AZN)Leerink Swann Comments on AstraZeneca plc's Q1 2018 Earnings (AZN)
www.americanbankingnews.com - February 7 at 8:28 AM
AstraZeneca (AZN) Price Target Raised to $38.00 at Leerink SwannAstraZeneca (AZN) Price Target Raised to $38.00 at Leerink Swann
www.americanbankingnews.com - February 6 at 7:54 PM
BNP Paribas says it posted a 'solid' 2017 despite profit slump in last quarterBNP Paribas says it posted a 'solid' 2017 despite profit slump in last quarter
finance.yahoo.com - February 6 at 3:40 PM
AstraZeneca plc (AZN) Announces $0.95 Semiannual DividendAstraZeneca plc (AZN) Announces $0.95 Semiannual Dividend
www.americanbankingnews.com - February 5 at 8:16 PM
How Did Vertex Pharmaceuticals Perform in 4Q17 and 2017?How Did Vertex Pharmaceuticals Perform in 4Q17 and 2017?
finance.yahoo.com - February 5 at 3:38 PM
AstraZeneca (AZN) PT Raised to $42.00 at Sanford C. BernsteinAstraZeneca (AZN) PT Raised to $42.00 at Sanford C. Bernstein
www.americanbankingnews.com - February 5 at 12:12 PM
Novartis’s 4Q17 Earnings: Alcon BusinessNovartis’s 4Q17 Earnings: Alcon Business
finance.yahoo.com - February 5 at 9:16 AM
AstraZenecas (AZN) Buy Rating Reaffirmed at BMO Capital MarketsAstraZeneca's (AZN) Buy Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - February 4 at 8:10 PM
AstraZeneca (AZN) Upgraded at ValuEngineAstraZeneca (AZN) Upgraded at ValuEngine
www.americanbankingnews.com - February 3 at 2:32 PM
Is AstraZeneca PLC (LON:AZN) An Attractive Dividend Stock?Is AstraZeneca PLC (LON:AZN) An Attractive Dividend Stock?
finance.yahoo.com - February 3 at 9:08 AM
AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over TesaroAstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro
finance.yahoo.com - February 2 at 3:45 PM
FTSE 100 suffers worst week since April as bond yields spikeFTSE 100 suffers worst week since April as bond yields spike
finance.yahoo.com - February 2 at 3:45 PM
Novartis’s 4Q17 Earnings: Segment-Wise RevenuesNovartis’s 4Q17 Earnings: Segment-Wise Revenues
finance.yahoo.com - February 2 at 3:45 PM
AstraZeneca (AZN) Updates FY18 Earnings GuidanceAstraZeneca (AZN) Updates FY18 Earnings Guidance
www.americanbankingnews.com - February 2 at 11:14 AM
AstraZeneca (AZN) Announces Quarterly  Earnings Results, Beats Expectations By $0.86 EPSAstraZeneca (AZN) Announces Quarterly Earnings Results, Beats Expectations By $0.86 EPS
www.americanbankingnews.com - February 2 at 10:40 AM
AstraZeneca Q4 Pre-tax Profit Plunges, Revenues Up; Warns On FY18 Core EPSAstraZeneca Q4 Pre-tax Profit Plunges, Revenues Up; Warns On FY18 Core EPS
www.nasdaq.com - February 2 at 9:02 AM
Should you invest in AstraZeneca plc right now?Should you invest in AstraZeneca plc right now?
uk.finance.yahoo.com - February 2 at 9:02 AM
Astrazeneca beats 4Q profit forecastsAstrazeneca beats 4Q profit forecasts
finance.yahoo.com - February 2 at 9:02 AM
FTSE 100 heads for worst week in six months as results dragFTSE 100 heads for worst week in six months as results drag
finance.yahoo.com - February 2 at 9:02 AM
AstraZeneca flags return to drug sales growth in 2018AstraZeneca flags return to drug sales growth in 2018
finance.yahoo.com - February 2 at 9:02 AM
AstraZeneca links with Alibaba and Tencent in China pushAstraZeneca links with Alibaba and Tencent in China push
finance.yahoo.com - February 2 at 9:02 AM
AstraZeneca flags return to drug sales growth in 2018, at a priceAstraZeneca flags return to drug sales growth in 2018, at a price
finance.yahoo.com - February 2 at 9:02 AM
Contrasting AstraZeneca (AZN) and BioLife Solutions (BLFS)Contrasting AstraZeneca (AZN) and BioLife Solutions (BLFS)
www.americanbankingnews.com - February 1 at 5:22 PM
Allergan (AGN) to Report Q4 Earnings: Whats in the Cards?Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
finance.yahoo.com - February 1 at 3:40 PM
What to watch in AstraZeneca earningsWhat to watch in AstraZeneca earnings
www.marketwatch.com - February 1 at 9:16 AM
Comparing AstraZeneca (AZN) and Concordia International (CXRX)Comparing AstraZeneca (AZN) and Concordia International (CXRX)
www.americanbankingnews.com - January 31 at 1:18 AM
 Analysts Anticipate AstraZeneca plc (AZN) Will Post Quarterly Sales of $5.76 Billion Analysts Anticipate AstraZeneca plc (AZN) Will Post Quarterly Sales of $5.76 Billion
www.americanbankingnews.com - January 30 at 4:20 AM
 Analysts Expect AstraZeneca plc (AZN) Will Announce Earnings of $0.44 Per Share Analysts Expect AstraZeneca plc (AZN) Will Announce Earnings of $0.44 Per Share
www.americanbankingnews.com - January 28 at 3:18 PM
AstraZeneca plc isn’t the only way to play the world’s ageing populationAstraZeneca plc isn’t the only way to play the world’s ageing population
uk.finance.yahoo.com - January 28 at 9:08 AM
AstraZeneca sees positive lung-treatment resultsAstraZeneca sees positive lung-treatment results
www.marketwatch.com - January 26 at 8:52 AM
AstraZenecas 3-in-1 inhaler helps COPD patients in trialAstraZeneca's 3-in-1 inhaler helps COPD patients in trial
finance.yahoo.com - January 26 at 8:52 AM
U.K. stocks rebound from 1-month low as AstraZeneca rises after trial resultsU.K. stocks rebound from 1-month low as AstraZeneca rises after trial results
finance.yahoo.com - January 26 at 8:52 AM
BMO Capital Markets Reiterates "Buy" Rating for AstraZeneca (AZN)BMO Capital Markets Reiterates "Buy" Rating for AstraZeneca (AZN)
www.americanbankingnews.com - January 26 at 8:46 AM
AstraZeneca (AZN) Set to Announce Quarterly Earnings on FridayAstraZeneca (AZN) Set to Announce Quarterly Earnings on Friday
www.americanbankingnews.com - January 26 at 1:14 AM
Interesting AZN Put And Call Options For March 9thInteresting AZN Put And Call Options For March 9th
www.nasdaq.com - January 25 at 3:41 PM

SEC Filings

AstraZeneca (NYSE:AZN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AstraZeneca (NYSE:AZN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AstraZeneca (NYSE AZN) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.